MyChesCo on MSN3h
Johnson & Johnson Reports Positive Study Results for Ulcerative Colitis Treatment
Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...
Zacks Investment Research on MSN2d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated ...
PharmExec2d
Icotrokinra Demonstrates Promise in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
Applied Clinical Trials Online1d
Johnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.
GlobalData on MSN3d
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...
Johnson & Johnson's Ulcerative Colitis Drug Hits Key Trial Goals, Stock Rises
JNJ's ulcerative colitis drug shows promise in mid-stage trials, with high response rates and well-tolerated safety profile ...
Protagonist reports top line results from Phase 2b study of icotrokinra
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
Nasdaq4d
Johnson & Johnson Reports Positive Topline Results For Icotrokinra In Ulcerative Colitis
in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint of clinical response in all icotrokinra dose groups evaluated and demonstrated clinically ...
Investing4d
Icotrokinra shows promise in ulcerative colitis study
highlighted icotrokinra’s potential to change the treatment landscape for UC, citing its combination of efficacy, tolerability, and convenient once-daily oral dosing. Ulcerative colitis is a ...
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $80 from $54 and keeps a Buy rating on the shares. The ...
Nasdaq2d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra ... to severely active ulcerative colitis (UC), a chronic ...